Deutsch English Français

Contact

EP3484466

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3484466

EP3484466 - COMBINATION OF SPLEEN TYROSINE KINASE INHIBITORS AND OTHER THERAPEUTIC AGENTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 24.01.2020 Database last updated on 25.09.2024
Former	Request for examination was made Status updated on 19.04.2019
Former	The international publication has been made Status updated on 20.01.2018
Former	unknown Status updated on 20.06.2017
Most recent event Tooltip	24.01.2020	Application deemed to be withdrawn	published on 26.02.2020 [2020/09]
Applicant(s)	For all designated states Takeda Pharmaceutical Company Limited 1-1 Doshomachi 4-chome Chuo-ku Osaka-shi, Osaka 541-0045 / JP
	[2019/21]
Inventor(s)	01 / BRAKE, Rachael, L. 21 Manchester Place Natick, MA 01760 / US
	02 / SAPPAL, Jessica J. 87 Nowell Road Wakefield, MA 02148 / US
	03 / KANNAN, Karuppiah 47 Auburn Street Newton, MA 02465 / US
	04 / SHOU, Yaping 293 Sargent Road Boxborough, MA 01719 / US
	[2019/21]
Representative(s)	Jones Day Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11 80538 München / DE
	[2019/21]
Application number, filing date	17728976.6	26.05.2017
	[2019/21]
	WO2017US34805
Priority number, date	US201662361999P	13.07.2016 Original published format: US 201662361999 P
	US201662425578P	22.11.2016 Original published format: US 201662425578 P
	[2019/21]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2018013239
	Date:	18.01.2018
	Language:	EN
	[2018/03]
	Type:	A1 Application with search report
	No.:	EP3484466
	Date:	22.05.2019
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 18.01.2018 takes the place of the publication of the European patent application.
	[2019/21]
Search report(s)	International search report - published on:	EP	18.01.2018
Classification	IPC:	A61K31/196, A61K31/198, A61K31/4184, A61K31/437, A61K31/513, A61K31/496, A61K31/675, A61K45/06, A61K31/454, A61K31/519, A61K39/395, A61K31/7068, A61P35/00, A61P35/02	[2019/21]
	CPC:	A61K31/437 (EP,US); A61K31/196 (EP,US); A61K31/198 (EP,US); A61K31/4184 (EP,US); A61K31/454 (EP,US); A61K31/496 (EP,US); (+) A61K31/513 (EP,US); A61K31/519 (EP,US); A61K31/675 (EP,US); A61K31/7068 (EP,US); A61K39/395 (US); A61K39/39558 (US); A61K45/06 (EP,US); A61P35/00 (EP,US); C07K16/2818 (US); C07K16/2887 (US); A61K9/0053 (US) (-)
	C-Set:	A61K31/196, A61K2300/00 (US,EP); A61K31/198, A61K2300/00 (EP,US); A61K31/4184, A61K2300/00 (US,EP); A61K31/437, A61K2300/00 (US,EP); (+) A61K31/454, A61K2300/00 (EP,US); A61K31/496, A61K2300/00 (US,EP); A61K31/513, A61K2300/00 (US,EP); A61K31/519, A61K2300/00 (US,EP); A61K31/675, A61K2300/00 (EP,US); A61K31/7068, A61K2300/00 (US,EP); A61K39/39558, A61K2300/00 (EP,US); A61K39/395, A61K2300/00 (EP,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/21]
Title	German:	KOMBINATION AUS MILZ-TYROSIN-KINASE-INHIBITOREN UND ANDEREN THERAPEUTIKA	[2019/21]
	English:	COMBINATION OF SPLEEN TYROSINE KINASE INHIBITORS AND OTHER THERAPEUTIC AGENTS	[2019/21]
	French:	COMBINAISON D'INHIBITEURS DE LA TYROSINE KINASE DE LA RATE ET D'AUTRES AGENTS THÉRAPEUTIQUES	[2019/21]
Entry into regional phase	11.01.2019	National basic fee paid
	11.01.2019	Designation fee(s) paid
	11.01.2019	Examination fee paid
Examination procedure	11.01.2019	Examination requested [2019/21]
	11.01.2019	Date on which the examining division has become responsible
	03.09.2019	Application deemed to be withdrawn, date of legal effect [2020/09]
	03.09.2019	Loss of particular rights, legal effect: Claims
	10.10.2019	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time [2020/09]
	10.10.2019	Despatch of communication of loss of particular rights: Claims {1}
Fees paid	Renewal fee
	28.05.2019	Renewal fee patent year 03
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XYI]US2011152273 (ARIKAWA YASUYOSHI [JP], et al) [X] 1,2,4,7,10,13,14,16,19,20,51,52 * page 1, paragraph 2 * * page 5, paragraphs 157, 161 * * page 25, paragraph 304 * * page 26, paragraph 309 * * page 26, paragraph 315 - paragraph 316 * * page 48; example 28 * * claim 32 * [Y] 21-25,36,37 [I] 3,5,6,8,9,11,12,15,17,18,44-50,53,54;
		[XYI]WO2012044936 (PORTOLA PHARM INC [US], et al) [X] 1,2,7,13,14,19-21,50-52 * page 5, paragraph 15 * * page 6, paragraph 20 - page 7, paragraph 21 * * page 8, paragraph 30 * * page 9, paragraph 35 * * page 11, paragraph 64 * * page 12, paragraph 66 * * page 25, paragraph 139 * * claims 15, 17, 28, 30, 32 * [Y] 4,5,10,11,16,17,22-25,37 [I] 3,6,8,9,12,15,18,36,44-49,53,54;
		[Y]WO2015138199 (VOUDOURIS VASILIOS [US]) [Y] 1-25,36,37,44-54 * claims 1-3, 78-80 *;
		[Y]WO2015164330 (MILLENNIUM PHARM INC [US]) [Y] 1-25,36,37,44-54 * page 7, line 17 - line 22 * * page 13, line 19 - line 21 * * page 32, line 18 - line 24 * * claims 36, 43, 45 *;
		[Y]US2016176869 (CHEN RONGLIANG [US], et al) [Y] 1-25,36,37,44-54 * claims 1, 14, 16, 17 *;
		[XYI] - ROSSI RANDAL ET AL, "Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma. \| Blood Journal", BLOOD, (20091101), vol. 114, no. 22, ISSN 0006-4971, XP055392850 [X] 1-3,7-9,13-15,19-21 * page 1, line 4 - line 8 * * page 2, line 7 - line 31 * * page 3, line 9 - line 12 * [Y] 4,5,10,11,16,17,22-25,37 [I] 6,12,18,36,44-54
		[XYI] - KAZUMI HAGIWARA ET AL, "Cytotoxic Effect of Bendamustine Combined with Kinase Inhibitors in Hematologic Cell Lines \| Blood Journal", BLOOD, United States, (20120101), vol. 120, no. 21, ISSN 1528-0020, page 4912, XP055392669 [X] 1-3,7-9,13-15,19-21 * page 2, line 2 - line 10 * * page 2, line 26 - line 28 * [Y] 4,5,10,11,16,17,22-25,37 [I] 6,12,18,36,44-54
		[XYI] - NOELIA PURROY, "Syk Inhibition By TAK-659 Overcomes Proliferative, Survival and Migratory Signals from the Microenvironment in Chronic Lymphocytic Leukemia Cells", BLOOD, (20141206), vol. 124, no. 21, XP055304217 [X] 1,2,4 * page 2, line 5 - line 15 * * page 3, line 1 - line 4 * [Y] 4,5,13,14,16-25,36,37 [I] 5,6,45-54
		[Y] - HARRISON ANDREW M ET AL, "Rituximab for Non-Hodgkin's Lymphoma: A Story of Rapid Success in Translation", CTS-CLINICAL AND TRANSLATIONAL SCIENCE, (201402), vol. 7, no. 1, pages 82 - 86, XP002772526 [Y] 22-25,37 * abstract * * page 82, column right, line 1 - line 16 * * page 84, column left, line 26 - line 28 * * page 85, line 7 - line 9 * DOI: http://dx.doi.org/10.1111/cts.12111
	by applicant	WO2011022439
		WO2011079051
		US8440689
		- TURNER et al., Immunology Today, (20000000), vol. 21, no. 3, pages 148 - 154
		- SANDERSON et al., Inflammation & Allergy - Drug Targets, (20090000), vol. 8, pages 87 - 95
		- HAHN et al., Cancer Cell, (20090000), vol. 16, pages 281 - 294
		- CHU et al., Immunol. Rev, (19980000), vol. 165, pages 167 - 180
		- FELDMAN et al., Leukemia, (20080000), vol. 22, pages 1139 - 1143
		- RINALDI et al., Br. J. Haematol., (20060000), vol. 132, pages 303 - 316
		- STREUBEL et al., Leukemia, (20060000), vol. 20, pages 313 - 318
		- BUCHNER et al., Cancer Research, (20090000), vol. 69, no. 13, pages 5424 - 5432
		- BAUDOT et al., Oncogene, (20090000), vol. 28, pages 3261 - 3273
		- SINGH et al., Cancer Cell, (20090000), vol. 15, pages 489 - 500
		- BERGE et al., J. Pharm. Sci, (19770000), vol. 66, pages 1 - 19
		- CHESON et al., J. Clin. Oncol., (20070000), vol. 25, no. 5, pages 579 - 586
		- OKEN et al., Am. J. Clin. Oncol., (19820000), vol. 5, no. 6, pages 649 - 655
		- COCKCROFT et al., Nephron, (19760000), vol. 16, no. 1, pages 31 - 41
		- "The Criteria Committee of New York Heart Association", Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, Little, Brown & Co, (19940000), pages 253 - 256
		- "Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Draft Guidance", U.S. Food and Drug Administration, URL: http://www.fda.gOv/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
		- "Drug Development and Drug Interactions", U.S. Food and Drug Administration, URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/%20DrugInteractionsLabeling/ucm080499.htm
		- RUMMEL et al., J. Clin. Oncol., (20050000), vol. 23, no. 15, pages 3383 - 3389
		- VACIRCA et al., Ann. Hematol., (20140000), vol. 93, no. 3, pages 403 - 409
		- LECHNER et al., J. Transl. Med., (20110000), vol. 9, page 90
		- COTECHINI et al., Cancer. J., (20150000), vol. 21, no. 4, pages 343 - 350
		- DILILLO et al., J. Immunol., (20100000), vol. 184, no. 7, pages 4006 - 4016
		- LUGER et al., PLoS One, (20130000), vol. 8, no. 10, page e76115
		- EISENHAUER et al., Eur. J. Cancer, (20090000), vol. 45, no. 2, pages 228 - 247
		- CHESON BD et al., J. Clin. Oncol., (20070000), vol. 25, no. 5, pages 579 - 586

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p